Masimo reports Q2 EPS 62c, consensus 56c

Reports Q2 revenue $455.3M, consensus $478.35M. The company said, “Second quarter 2023 was a tale of two realities. Our healthcare revenues and earnings declined sequentially and annually, but we gained new hospital customers at a record level, despite strong results in the prior three years, and retained existing hospital customers. We are disappointed with our results this quarter. Our updated guidance assumes inpatient volumes will not return to the levels we expected this year and we will not receive some of the new large orders we are expecting for W1, Rad-G and Rad-97.”